For patients with unresectable colorectal liver metastases (uCRLM), regional therapies
leverage the unique, dual blood supply to the liver; the hepatic artery is the main blood …

Introduction Implantable devices can be designed to release drugs to localized regions of
tissue at sustained and reliable rates. Advances in polymer engineering have led to the …

Cholangiocarcinoma (CCA) is the second most common primitive liver cancer. Despite
recent advances in the surgical management, the prognosis remains poor, with a 5-year …

Background Hepatic artery infusion pump (HAIP) therapy has become increasingly
commonplace in the treatment of intrahepatic tumors. When combined with standard …

The treatment of unresectable colorectal liver metastasis (CRLM) has previously been
limited to palliative chemotherapy. Traditionally, the role of liver transplant has not been …

In the 1940s, the newly discovered chemotherapy agents were administered intravenously.
2 By the middle of the century, physicians and scientists were searching for ways to achieve …

Distinct from industry and cooperative group clinical trials, investigator-initiated trials (IITs)
are unsolicited trials designed and led by physicians that positively impact current clinical …

Simple Summary Local treatments represent a potential curative approach in the patient with
liver metastases of colorectal origin. It is important for all the team involved in patient care to …

Simple Summary Liver metastasis is a major therapeutic challenge and common cause of
death for patients with colorectal cancer. While systemic treatment especially chemotherapy …

Implementation of a successful hepatic artery infusion pump program requires numerous
factors to be in place, and the lack of any of these may lead to program failure. First and …